TASIGNA Drug Patent Profile

When do Tasigna patents expire, and what generic alternatives are available?

Tasigna is a drug marketed by Novartis and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-one patent family members in fifty countries.

The generic ingredient in TASIGNA is nilotinib hydrochloride. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tasigna

A generic version of TASIGNA was approved as nilotinib hydrochloride by APOTEX on January 5^th, 2024.

Summary for TASIGNA

International Patents:	231
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	68
Patent Applications:	3,868
Drug Prices:	Drug price information for TASIGNA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TASIGNA
What excipients (inactive ingredients) are in TASIGNA?	TASIGNA excipients list
DailyMed Link:	TASIGNA at DailyMed

See drug prices for TASIGNA

Recent Clinical Trials for TASIGNA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Xspray Pharma AB	PHASE1
Kartos Therapeutics, Inc.	Phase 1/Phase 2
Baylor College of Medicine	Phase 2

See all TASIGNA clinical trials

Pharmacology for TASIGNA

Drug Class	Kinase Inhibitor
Mechanism of Action	Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors P-Glycoprotein Inhibitors UGT1A1 Inhibitors

Paragraph IV (Patent) Challenges for TASIGNA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TASIGNA	Capsules	nilotinib hydrochloride	50 mg	022068	1	2019-10-17
TASIGNA	Capsules	nilotinib hydrochloride	150 mg and 200 mg	022068	1	2013-11-08

US Patents and Regulatory Information for TASIGNA

TASIGNA is protected by six US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No

International Patents for TASIGNA

When does loss-of-exclusivity occur for TASIGNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TASIGNA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	040390	INHIBIDORES DE QUINASAS DE TIROSINA
Austria	414699
Australia	2003249962	INHIBITORS OF TYROSINE KINASES
Brazil	0312464	Inibidores de tirosina quinases

TASIGNA (nilotinib) Market Dynamics and Financial Trajectory: Exclusivity, Patent/Generic Risk, and Revenue Outlook (Global and US)

Last updated: July 21, 2026

Tasigna (nilotinib) remains a high-value oncology asset in chronic myeloid leukemia (CML) and is priced and defended through a mature, multi-layer patent estate, coupled with ongoing US FDA oversight and generic entry gating via Orange Book-listed patents and litigation. The drug’s financial trajectory has shifted from early growth to maturity dynamics, with revenue increasingly driven by the ongoing mix of CML subpopulations (treatment-naïve vs. resistant/intolerant) and by discounting, payer contracting, and competitive positioning versus other BCR-ABL tyrosine kinase inhibitors (TKIs), particularly imatinib, dasatinib, bosutinib, and ponatinib.

---

How has Tasigna’s global revenue trended and what drives profitability?

Featured snippet answer: Tasigna’s financial trajectory is maturity-stage oncology: revenue is sustained by patient persistence on treatment and by CML segment mix (newly diagnosed and post-imatinib failures), while profitability is pressured by TKI competition, contractual discounting, and volume elasticity in branded oncology.

Revenue drivers

1. Patient mix within CML

   • Treatment-naïve chronic-phase CML (CP-CML) and accelerated-phase/blast-phase use patterns affect net price and persistence.
   • Resistant/intolerant populations often show higher persistence, improving net revenue durability.

2. Net price vs list price

   • Branded oncology TKIs typically deliver revenue under payer rebates, hospital/IDN contracting, and sequencing discounts.
   • Growth from new prescribers is usually slower than loss from competing TKI preference shifts.

3. Cross-TKI switching

   • Prescribers adjust TKIs based on efficacy, adverse event profile, dosing schedule, and comorbidity tolerance.
   • Competition from dasatinib and bosutinib impacts share in chronic-phase settings; ponatinib is a later-line option in certain mutation contexts.

Cost and operating leverage (profit trajectory)

• Tyrosine kinase inhibitor manufacturing is largely mature and scale-driven; gross margin tends to remain stable once active ingredient supply chains are optimized.
• SG&A scales less than revenue in stable branded lifecycle phases, supporting operating leverage if volumes hold.

---

What patents protect Tasigna and how strong is the patent estate for nilotinib?

Featured snippet answer: Tasigna’s protection is sustained by a layered estate covering composition of matter, formulations, and additional patentable subject matter such as methods of use and treatment regimens. The estate’s strength is typically measured by Orange Book coverage depth around each approved indication and dosage form, plus active litigation that blocks or delays generic launches.

Key patent categories that typically keep Tasigna defended

• Compositions of matter (nilotinib and related chemical entities)
• Pharmaceutical compositions/formulations (e.g., capsule-specific compositions, physical-chemical characteristics, and drug-release attributes)
• Methods of treatment (CML treatment regimens, dosing strategies, and potentially mutation-specific or line-of-therapy methods)
• Manufacturing/process (less commonly the primary driver for TKI lifecycle, but often present)

Practical market impact of “estate depth”

• A “thin” estate tends to translate into earlier generic entry via Paragraph IV or narrow approval at-risk of noninfringement.
• A “deep” estate translates into fewer safe generic launch pathways and higher settlement leverage for the brand.

---

What is the Orange Book status of Tasigna in the US?

Featured snippet answer: Tasigna is listed in FDA’s Orange Book with multiple patents covering approved dosage forms and uses. Generic entry is typically blocked by the need to address each listed patent for each dosage form and by the Hatch-Waxman litigation process.

Why Orange Book granularity matters

• Generics must carve out or litigate against listed patents tied to the specific strength/dosage form they seek.
• Multi-patent listings increase the probability of at least one active infringement/validity dispute that can trigger exclusivity stays.

Expected US lifecycle dynamics for a defended TKI

• Even after composition-of-matter expiration, formulation and method-of-use patents can maintain barriers.
• Settlement agreements can narrow at-risk launch windows and reframe which generic label entries occur first.

---

When does Tasigna lose exclusivity in the US and what are the key timing milestones?

Featured snippet answer: Tasigna’s exclusivity timeline is structured by (1) the earliest composition-of-matter expiration, (2) the coverage end dates for Orange Book-listed formulation and method-of-use patents, and (3) Hatch-Waxman litigation and any pediatric exclusivity/marketing exclusivity extensions that can extend protection.

Timing milestones that determine generic launch windows

• Composition-of-matter expiration date for nilotinib-related claims
• Drug product/formulation patent expirations for capsule dosage forms
• Method-of-use patent expirations tied to approved CML treatment settings
• Orange Book listed patent expiration and court-managed stays
• Potential pediatric exclusivity windows if applicable and tied to labeling

(Exact dates must be pulled from the Orange Book patent listing record for the relevant strengths and dosage forms; this response does not provide date values.)

---

Have there been Paragraph IV challenges to Tasigna, and how have they affected generic risk?

Featured snippet answer: Paragraph IV challenges, when successful or when litigation ends favorably for challengers, can catalyze generic launch. For Tasigna, generic risk is typically governed by whether challengers cleared all relevant Orange Book patents and by settlement terms that can delay market entry.

How to read the generic risk signal

• A single settlement often delays the first-attempt generic entry even if some patents fall out.
• A “multi-challenge” landscape can create a rolling window of entry risk, though settlement can still push approvals into later calendar periods.

---

What patent litigation affects Tasigna, and what settlement patterns matter for market entry?

Featured snippet answer: Tasigna’s generic entry trajectory depends on active Hatch-Waxman litigation over Orange Book patents, settlement agreements that set delayed-launch dates, and court outcomes that determine whether at-risk generic supply is permitted during the remaining protection term.

Litigation dynamics that shape the financial profile

• Automatic 30-month stay after a Paragraph IV filing can postpone FDA approval decisions.
• Consent judgments and settlements can set “drop dead” dates that brands use to preserve revenue.
• Final written judgments can either open a narrow label/carve-out or block entry until later expirations.

---

What formulations are protected for Tasigna, and how do formulation patents change generic entry barriers?

Featured snippet answer: Formulation patents for Tasigna’s capsules can limit generic launch by requiring generic products to demonstrate non-infringement or invalidity for drug product claim coverage tied to specific dosage forms, release characteristics, or capsule composition.

Formulation barrier effect

• If formulation patents remain active, generic manufacturers face:
  • additional litigation,
  • design-around efforts,
  • or settlement-driven delayed launches.

Dosage form-specific risk

• For branded oncology capsules, the risk often differs by strength (e.g., 150 mg, 200 mg, 50 mg combinations historically used in some regimens), but the key point is Orange Book coverage is usually claim-by-claim, strength-by-strength.

---

How does Tasigna compare with other BCR-ABL TKIs on market share dynamics?

Featured snippet answer: Tasigna competes with imatinib, dasatinib, bosutinib, and ponatinib. Market share is driven by efficacy outcomes, tolerability profile, dosing convenience, and payer contracting rather than by a single dimension.

Competitive positioning levers

• Efficacy and durability in chronic phase and in resistant/intolerant settings.
• Safety profile influencing switching behavior:
  • cardiovascular risk management has historically mattered for nilotinib prescribing.
  • dasatinib’s pleural effusion risk and bosutinib’s GI tolerability can shift comparative preference.
• Treatment sequencing and guideline adherence
  • CML treatment algorithms influence which drug is selected first-line versus later-line.

Practical effect on financial trajectory

• When competitor adoption rises in a specific subpopulation, Tasigna net price can be pressured.
• Conversely, strong persistence and limited switching in stable cohorts supports revenue durability.

---

What is the biosimilar risk for Tasigna?

Featured snippet answer: Tasigna is a small-molecule drug. Biosimilar risk is not a relevant pathway. The competitive threat is generic small-molecule entry and potentially authorized generics, not biosimilars.

---

What generic entry risks exist for Tasigna and what launch scenarios are most likely?

Featured snippet answer: Generic entry scenarios generally fall into three buckets: (1) launch after all relevant Orange Book patents expire, (2) launch after favorable litigation clears all asserted patents for a specific strength/dosage form, or (3) launch under settlement terms that set a delayed entry date.

Most likely commercial scenarios

1. Delayed entry through settlement
   • Keeps brand revenues protected through the settlement “delay period.”
2. Partial entry
   • A generic may launch for certain strengths only if other patents or labeling limitations remain.
3. At-risk launch
   • Less common when the brand has a deep estate and has strong litigation leverage.

---

What licensing deals and authorized generic structures can influence Tasigna’s revenue?

Featured snippet answer: Authorized generics and licensing arrangements can soften net revenue erosion by controlling supply timing and pricing. Where present, they reduce competitive shock compared with fully unlicensed generic launches.

How licensing shifts economics

• Authorized generics tend to compress branded revenue but can preserve stable total market share and reduce payer disruption.
• Settlement agreements can create a de facto “timeline” for erosion.

(Specific deal data requires Orange Book + litigation docket + company disclosures; this response does not assert deal terms.)

---

What regulatory status does Tasigna have with FDA and how does it affect competition?

Featured snippet answer: Tasigna remains an FDA-approved product; regulatory status affects generic labeling and interchangeability only insofar as FDA approval pathways and patent certifications govern entry timing.

FDA pathway implications

• Generics typically use abbreviated new drug applications (ANDAs).
• Hatch-Waxman certifications and patent challenges are the legal gatekeepers to approval timing, not routine regulatory reapproval events.

---

How do manufacturing and IP barriers affect generic feasibility for Tasigna?

Featured snippet answer: Even if patents clear, generic feasibility depends on manufacturing capability, bioequivalence demonstration, and formulation scaling for capsule product quality. IP barriers raise pre-launch litigation and design-around costs.

Operational friction points

• Capsule formulation reproducibility and dissolution performance can be a technical barrier.
• Supply chain capacity and quality systems must meet FDA standards quickly once a launch is permitted.

---

Global market dynamics: which regions matter and how does patent coverage vary?

Featured snippet answer: Revenue exposure is concentrated in major markets with strong IP enforcement (US, EU, Japan, and other high-value territories). Patent term differences and enforcement timelines can create region-specific generic entry risk.

Cross-jurisdiction pattern

• US patent life and Orange Book gating often determine the first significant commercial erosion for nilotinib.
• EU and Japan can maintain parallel protection via different patent types and different enforcement timelines.

---

Key quantitative reference table: what to monitor for Tasigna’s financial trajectory

Category	What to track	Why it moves revenue
Net price & discounts	payer contracting and rebate rate changes	drives revenue without requiring volume growth
Patient persistence	time-on-treatment and switching rate to other TKIs	branded lifecycle stability
Segment mix	treatment-naïve vs resistant/intolerant volumes	impacts net pricing and continuity
FDA/Orange Book status	listed patent expirations by strength	determines generic launch calendar
Hatch-Waxman events	Paragraph IV filings, 30-month stays, court outcomes	changes timing of first generic revenue erosion
Settlement agreements	delayed-entry dates and carve-outs	sets “duration of protection” in practice
Competitor share	uptake of dasatinib/bosutinib/ponatinib	drives volume and contracting leverage
Safety-driven prescribing	cardiometabolic risk management patterns	affects switching and adherence

---

Key Takeaways

• Tasigna’s market dynamics are dominated by mature branded oncology economics: stable persistence can sustain revenue even as TKI competition intensifies.
• Generic entry risk is governed by US Orange Book depth and Hatch-Waxman litigation over nilotinib-associated patents, including formulation and method-of-use coverage that can delay ANDA approvals.
• Financial trajectory depends on (1) net pricing and rebates, (2) CML segment mix, and (3) patient switching influenced by adverse event profiles and guideline-driven sequencing.
• Biosimilar risk is not applicable; the threat is generic small-molecule entry and any authorized-generic or settlement structures that change launch timing and pricing.

---

FAQs

1) What patents protect nilotinib for CML treatment in the US?
Tasigna’s protection typically includes composition-of-matter, formulation, and method-of-use patents listed in the FDA Orange Book for the approved capsule dosage forms and indications.

2) When do Tasigna generic ANDAs become feasible under Hatch-Waxman?
Generic ANDAs typically become launch-feasible only after the last relevant Orange Book patent expires or after litigation/settlement clears all asserted patents for the requested strength and label scope.

3) Does nilotinib face biosimilar competition?
No. Nilotinib is a small molecule, so competition comes from generic small-molecule ANDAs, not biosimilars.

4) How does switching between BCR-ABL TKIs affect Tasigna revenue?
Switching is driven by safety tolerability, comorbidity management, and guideline sequencing. Increased adoption of competing TKIs in specific CML subpopulations can pressure volume and net price.

5) What are the main commercial impacts of settlement agreements on Tasigna?
Settlements can delay entry dates, restrict label scope, and reduce immediate price shock compared with unscheduled court-driven launch timing.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
2. FDA. Hatch-Waxman Amendments and Paragraph IV Certifications. US Food and Drug Administration.
3. FDA. ANDA and Patent Certification Requirements (27-year framework, Orange Book). US Food and Drug Administration.

DrugChatter Q&A for TASIGNA

• tasigna date expiration brevetnovartis?
Tasigna generic available?
Why is tasigna so expensive?
When did tasigna become generic?
Tasigna patent expiry date?